Published • loading... • Updated
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026
BeOne said its solid tumor pipeline is advancing across multiple programs as it seeks clinical and commercial momentum with oncologists and investors.
Summary by Hastings Tribune
5 Articles
5 Articles
Hastings Tribune+3 Reposted by 3 other sources
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026
SAN CARLOS, Calif.--(BUSINESS WIRE)--Oct 19, 2026-
·Nebraska, United States
Read Full Article
New data from four priority programs, including the bispecific antibody GPC3x4-1BB, the CEA-targeted ADC, the CDK4 inhibitor, and the blood-brain barrier-crossing PRMT5 inhibitor, highlight the breadth of BeOne’s solid tumor pipeline. Multiple abstracts on TEVIMBRA confirm the breadth of the evidence for lung and gastrointestinal tumors, including data on the […]
Coverage Details
Total News Sources5
Leaning Left0Leaning Right1Center2Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
C 67%
R 33%
Factuality
To view factuality data please Upgrade to Premium
